Search Results - "Lee, Matthew Y"

Correction: Lymph node evaluation for endometrial hyperplasia: a nationwide analysis of minimally invasive hysterectomy in the ambulatory setting by Matsuo, Koji, Ciesielski, Katharine M., Mandelbaum, Rachel S., Lee, Matthew Y. W., Jooya, Neda D., Roman, Lynda D., Wright, Jason D.

Get full text

What the SELECT trial of semaglutide means for clinicians by Sattar, Naveed, Lee, Matthew M. Y., McGuire, Darren K.

“…Accumulating data support the systemic benefits of semaglutide (and potentially other GLP-1RA-based therapies) in people with obesity, meaning that…”
Get full text

Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes by Lee, Matthew M Y, Ghouri, Nazim, McGuire, Darren K, Rutter, Martin K, Sattar, Naveed

“…Results of cardiovascular outcome trials (CVOTs) suggest Asians may derive greater benefit than Whites from newer classes of antihyperglycemic medications. To…”
Get full text

Lack of Benefit of Renin-Angiotensin System Inhibitors in COVID-19 by Lee, Matthew M. Y, McMurray, John J. V

“…There has been considerable interest in the potential role of renin-angiotensin system (RAS) inhibitors in patients with COVIO-19 given that…”
Get full text

Revisiting Race and the Benefit of RAS Blockade in Heart Failure: A Meta-Analysis of Randomized Clinical Trials by Shen, Li, Lee, Matthew M. Y, Jhund, Pardeep S, Granger, Christopher B, Anand, Inder S, Maggioni, Aldo P, Pfeffer, Marc A, Solomon, Scott D, Swedberg, Karl, Yusuf, Salim, McMurray, John J. V

“…IMPORTANCE: Concerns have arisen that renin-angiotensin system (RAS) blockers are less effective in Black patients than non-Black patients with heart failure…”
Get full text

Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy by Maron, Martin S., Masri, Ahmad, Nassif, Michael E., Barriales-Villa, Roberto, Arad, Michael, Cardim, Nuno, Choudhury, Lubna, Claggett, Brian, Coats, Caroline J., Düngen, Hans-Dirk, Garcia-Pavia, Pablo, Hagège, Albert A., Januzzi, James L., Lee, Matthew M.Y., Lewis, Gregory D., Ma, Chang-Sheng, Michels, Michelle, Olivotto, Iacopo, Oreziak, Artur, Owens, Anjali T., Spertus, John A., Solomon, Scott D., Tfelt-Hansen, Jacob, van Sinttruije, Marion, Veselka, Josef, Watkins, Hugh, Jacoby, Daniel L., Heitner, Stephen B., Kupfer, Stuart, Malik, Fady I., Meng, Lisa, Wohltman, Amy, Abraham, Theodore P.

“…Among patients with symptomatic obstructive hypertrophic cardiomyopathy, treatment with aficamten led to a greater increase in peak oxygen consumption than…”
Get full text

Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial by Layland, Jamie, Oldroyd, Keith G, Curzen, Nick, Sood, Arvind, Balachandran, Kanarath, Das, Raj, Junejo, Shahid, Ahmed, Nadeem, Lee, Matthew M Y, Shaukat, Aadil, O'Donnell, Anna, Nam, Julian, Briggs, Andrew, Henderson, Robert, McConnachie, Alex, Berry, Colin

“…We assessed the management and outcomes of non-ST segment elevation myocardial infarction (NSTEMI) patients randomly assigned to fractional flow reserve…”
Get full text

Reducing Personal Exposure to Particulate Air Pollution Improves Cardiovascular Health in Patients with Coronary Heart Disease by LANGRISH, Jeremy P, XI LI, LIMING LI, MILLS, Nicholas L, NEWBY, David E, LIXIN JIANG, SHENGFENG WANG, LEE, Matthew M. Y, BARNES, Gareth D, MILLER, Mark R, CASSEE, Flemming R, BOON, Nicholas A, DONALDSON, Ken, JING LI

“…Air pollution exposure increases cardiovascular morbidity and mortality and is a major global public health concern. We investigated the benefits of reducing…”
Get full text

Advances in Multi-Modality Imaging in Hypertrophic Cardiomyopathy by Goldie, Fraser C, Lee, Matthew M Y, Coats, Caroline J, Nordin, Sabrina

“…Hypertrophic cardiomyopathy (HCM) is characterized by abnormal growth of the myocardium with myofilament disarray and myocardial hyper-contractility, leading…”
Get full text

Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis by Lee, Matthew M Y, Docherty, Kieran F, Sattar, Naveed, Mehta, Neil, Kalra, Ankur, Nowacki, Amy S, Solomon, Scott D, Vaduganathan, Muthiah, Petrie, Mark C, Jhund, Pardeep S, McMurray, John J V

“…Abstract Aims This meta-analysis provides summary odds ratio (OR) estimates for associations between treatment with (vs. without) renin–angiotensin system…”
Get full text

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials by Sattar, Naveed, Lee, Matthew M Y, Kristensen, Søren L, Branch, Kelley R H, Del Prato, Stefano, Khurmi, Nardev S, Lam, Carolyn S P, Lopes, Renato D, McMurray, John J V, Pratley, Richard E, Rosenstock, Julio, Gerstein, Hertzel C

“…GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes…”
Get full text

Diagnostic Accuracy of 3.0-T Magnetic Resonance T1 and T2 Mapping and T2-Weighted Dark-Blood Imaging for the Infarct-Related Coronary Artery in Non-ST-Segment Elevation Myocardial Infarction by Layland, Jamie, Rauhalammi, Samuli, Lee, Matthew M Y, Ahmed, Nadeem, Carberry, Jaclyn, Teng Yue May, Vannesa, Watkins, Stuart, McComb, Christie, Mangion, Kenneth, McClure, John D, Carrick, David, O'Donnell, Anna, Sood, Arvind, McEntegart, Margaret, Oldroyd, Keith G, Radjenovic, Aleksandra, Berry, Colin

“…Patients with recent non-ST-segment elevation myocardial infarction commonly have heterogeneous characteristics that may be challenging to assess clinically…”
Get full text

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF) by Lee, Matthew M.Y., Brooksbank, Katriona J.M., Wetherall, Kirsty, Mangion, Kenneth, Roditi, Giles, Campbell, Ross T., Berry, Colin, Chong, Victor, Coyle, Liz, Docherty, Kieran F., Dreisbach, John G., Labinjoh, Catherine, Lang, Ninian N., Lennie, Vera, McConnachie, Alex, Murphy, Clare L., Petrie, Colin J., Petrie, John R., Speirits, Iain A., Sourbron, Steven, Welsh, Paul, Woodward, Rosemary, Radjenovic, Aleksandra, Mark, Patrick B., McMurray, John J.V., Jhund, Pardeep S., Petrie, Mark C., Sattar, Naveed

“…Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure and reduced…”
Get full text

A review of current key guidelines for managing high‐risk patients with diabetes and heart failure and future prospects by Lee, Matthew M. Y., Sattar, Naveed

“…We reviewed recent guidelines on the management of heart failure (HF) in patients with diabetes. Major recommendations in European and US society guidelines…”
Get full text

Correction to: Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal Mine? by Lee, Matthew M. Y., Masri, Ahmad

Get full text

What's new in heart failure? October 2024 by Lee, Matthew M.Y., Codina, Pau, Tomasoni, Daniela, Aimo, Alberto

Get full text

Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations by Lee, Matthew M Y, Petrie, Mark C, Rocchiccioli, Paul, Simpson, Joanne, Jackson, Colette E, Corcoran, David S, Mangion, Kenneth, Brown, Ammani, Cialdella, Pio, Sidik, Novalia P, McEntegart, Margaret B, Shaukat, Aadil, Rae, Alan P, Hood, Stuart H M, Peat, Eileen E, Findlay, Iain N, Murphy, Clare L, Cormack, Alistair J, Bukov, Nikolay B, Balachandran, Kanarath P, Ford, Ian, Wu, Olivia, McConnachie, Alex, Barry, Sarah J E, Berry, Colin

“…BackgroundCoronary artery bypass graft (CABG) patients are under-represented in acute coronary syndrome (ACS) trials. We compared characteristics and outcomes…”
Get full text

What's new in heart failure? June–July 2024 by Aimo, Alberto, Codina, Pau, Lee, Matthew M.Y., Tomasoni, Daniela

Get full text

What's new in heart failure? May–June 2024 by Aimo, Alberto, Codina, Pau, Lee, Matthew M.Y., Tomasoni, Daniela

Get full text

How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials by Lee, Matthew M.Y., Petrie, Mark C., McMurray, John J.V., Sattar, Naveed

“…OBJECTIVE:There is substantial interest in how GLP-1RA (glucagon-like peptide-1 receptor agonists) and SGLT2 (sodium-glucose cotransporter 2) inhibitors reduce…”
Get full text